Kobayashi Pharmaceutical Co., Ltd.
KBYPFOTCConsumer Defensive● Active
$34.05
+$0.00(+0.00%)
Market Cap$2.5B
P/E Ratio—
52W High$37.43
52W Low$34.05
Kobayashi Pharmaceutical Co., Ltd. (KBYPF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
KBYPF · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 8, 2026EPS Actual
$0.09
Est. $0.03 · +159.3%
Revenue
$0.21B
Est. $0.21B · -0.9%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 8, 2026
After Market Close
▲ Beat EPS✓ 1-Quarter EPS Beat Streak
KBYPF reports quarterly as a OTC-listed Household & Personal Products company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$1.00
Rev. $1.80B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$1.00
Rev. Est.$1.80B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 11, 2026 | $0.15 | — | — | — | $0.24B | — |
| ▲ Q2 FY2026 | May 8, 2026 | $0.03 | $0.09 | +159.3% | $0.21B | $0.21B | -0.9% |
| ▼ Q1 FY2026 | Feb 10, 2026 | $0.52 | -$0.27 | -151.8% | $0.34B | $0.34B | +0.6% |
| ▲ Q4 FY2025 | Nov 11, 2025 | $0.30 | $0.33 | +11.6% | $0.29B | $0.35B | -16.3% |
| ▼ Q2 FY2025 | Jun 30, 2025 | $0.17 | $0.14 | -14.0% | $0.25B | $0.27B | -5.7% |
| ▼ Q1 FY2025 | Mar 31, 2025 | $0.33 | $0.15 | -55.0% | $0.22B | $0.24B | -4.8% |
| ▼ Q4 FY2024 | Dec 31, 2024 | $0.50 | $0.40 | -18.7% | $0.33B | $0.33B | -2.5% |
| ▼ Q3 FY2024 | Sep 30, 2024 | $0.57 | $0.35 | -38.3% | $0.28B | $0.31B | -8.9% |
Q3 FY2026
Aug 11, 2026
EPS Actual
—
EPS Est.
$0.15
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 8, 2026Beat
EPS Actual
$0.09
EPS Est.
$0.03
EPS Surpr.
+159.3%
Revenue
$0.21B
Q1 FY2026
Feb 10, 2026Miss
EPS Actual
-$0.27
EPS Est.
$0.52
EPS Surpr.
-151.8%
Revenue
$0.34B
Q4 FY2025
Nov 11, 2025Beat
EPS Actual
$0.33
EPS Est.
$0.30
EPS Surpr.
+11.6%
Revenue
$0.29B
Q2 FY2025
Jun 30, 2025Miss
EPS Actual
$0.14
EPS Est.
$0.17
EPS Surpr.
-14.0%
Revenue
$0.25B
Q1 FY2025
Mar 31, 2025Miss
EPS Actual
$0.15
EPS Est.
$0.33
EPS Surpr.
-55.0%
Revenue
$0.22B
Q4 FY2024
Dec 31, 2024Miss
EPS Actual
$0.40
EPS Est.
$0.50
EPS Surpr.
-18.7%
Revenue
$0.33B
Q3 FY2024
Sep 30, 2024Miss
EPS Actual
$0.35
EPS Est.
$0.57
EPS Surpr.
-38.3%
Revenue
$0.28B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $46.04 | $46.90 | $48.17 | 1 |
| Q3 FY2026 | $47.36 | $48.25 | $49.55 | 1 |
| Q2 FY2026 | $23.67 | $24.12 | $24.77 | 1 |
| Q1 FY2026 | $5.31 | $5.41 | $5.56 | 1 |
| Q4 FY2025 | $80.36 | $81.87 | $84.08 | 1 |
| Q3 FY2025 | $43.63 | $44.56 | $45.48 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $55.3B | $56.1B | $57.3B | 2 |
| Q3 FY2026 | $44.3B | $45.0B | $46.2B | 5 |
| Q2 FY2026 | $37.3B | $37.8B | $38.3B | 5 |
| Q1 FY2026 | $33.0B | $34.2B | $34.9B | 4 |
| Q4 FY2025 | $52.5B | $53.4B | $54.0B | 4 |
| Q3 FY2025 | $43.7B | $44.1B | $44.5B | 4 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 8, 2026 | +159.3% | $34.05 | $34.05 | +0.00% |
| ▼ Q1 FY2026 | Feb 10, 2026 | -151.8% | $34.05 | $34.05 | +0.00% |
| ▲ Q4 FY2025 | Nov 11, 2025 | +11.6% | $34.62 | $34.62 | +0.00% |
| ▼ Q2 FY2025 | Jun 30, 2025 | -14.0% | $37.43 | $37.43 | +0.00% |
| ▼ Q1 FY2025 | Mar 31, 2025 | -55.0% | $37.43 | $37.43 | +0.00% |
| ▼ Q4 FY2024 | Dec 31, 2024 | -18.7% | $37.43 | $37.43 | +0.00% |
| ▼ Q3 FY2024 | Sep 30, 2024 | -38.3% | $32.49 | $32.49 | +0.00% |
| ▼ Q2 FY2024 | Jun 30, 2024 | -88.3% | $32.49 | $32.49 | +0.00% |
Q2 FY2026+0.00%
Report Date
May 8, 2026
EPS Beat/Miss
+159.3%
Price Before
$34.05
Price After
$34.05
Q1 FY2026+0.00%
Report Date
Feb 10, 2026
EPS Beat/Miss
-151.8%
Price Before
$34.05
Price After
$34.05
Q4 FY2025+0.00%
Report Date
Nov 11, 2025
EPS Beat/Miss
+11.6%
Price Before
$34.62
Price After
$34.62
Q2 FY2025+0.00%
Report Date
Jun 30, 2025
EPS Beat/Miss
-14.0%
Price Before
$37.43
Price After
$37.43
Q1 FY2025+0.00%
Report Date
Mar 31, 2025
EPS Beat/Miss
-55.0%
Price Before
$37.43
Price After
$37.43
Q4 FY2024+0.00%
Report Date
Dec 31, 2024
EPS Beat/Miss
-18.7%
Price Before
$37.43
Price After
$37.43
Q3 FY2024+0.00%
Report Date
Sep 30, 2024
EPS Beat/Miss
-38.3%
Price Before
$32.49
Price After
$32.49
Q2 FY2024+0.00%
Report Date
Jun 30, 2024
EPS Beat/Miss
-88.3%
Price Before
$32.49
Price After
$32.49
Avg Beat Reaction+0.00%
Avg Miss Reaction+0.00%
Beat Rate2 / 8 quarters
Largest Move+0.00% (Q2 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: KBYPF ends December
Kobayashi Pharmaceutical Co., Ltd. (KBYPF) most recently reported earnings on May 8, 2026 for Q2 FY2026, posting EPS of $0.09 — beating the analyst consensus of $0.03 by +159.3%. The next KBYPF earnings date is expected around September 1, 2026.
Each quarter, investors track KBYPF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. KBYPF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
KBYPF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
KBYPF earnings · 5 questionsKobayashi Pharmaceutical Co., Ltd.'s next earnings report is expected around September 1, 2026. KBYPF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; KBYPF historically reports after market close (AMC).
KBYPF earnings datewhen is KBYPF earningsKBYPF next earnings datewhen does KBYPF report earningsKBYPF earnings calendar
▸ Source: FMP · Kobayashi Pharmaceutical Co., Ltd. SEC filings · US GAAP · Kobayashi Pharmaceutical Co., Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026